7 results about "Matriptase" patented technology

To provide methods of identifying new substrates for proteases and methods of using these substrates in a variety of therapeutic, diagnostic and prophylactic indications.SOLUTION: The invention relates generally to: polypeptides that include a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA); activatable antibodies and other large molecules that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator; and methods of making these polypeptides that include the cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and methods of use in a variety of therapeutic, diagnostic and prophylactic indications.SELECTED DRAWING: Figure 4A

The present invention relates to a matriptase-2 (MT2) inhibitor, a TMPRSS6 inhibitor, a ferroportin blocker, or a hepcidin enhancer. In particular, the present invention relates to the use of compounds capable of reducing at least one of the following: systemic iron levels, transferrin saturation (Tsat), non-transferrin-bound iron (NTBI), and unstable plasma iron (LPI). This may occur by inhibiting the expression of a target gene, where the target gene may be a transmembrane protease, serine 6 (TMPRSS6). Furthermore, the present invention relates to compositions comprising the above compounds, and methods of using such compounds and / or compositions. Such use may include therapeutic use, for example, to reduce iron overload and prevent iron-related toxicity, before, during, or after chemotherapy pretreatment, stem cell transplantation, and engraftment.

Antibodies to the enzyme matriptase-2 (MTP-2) are presented. Inhibiting MTP-2 reduces uptake of dietary iron and reduces the release of iron from cellular stores in the body. Inhibitors of MTP-2 (such as antibodies to the serine protease domain) can be used to treat iron overload, which is a feature of diseases such as beta-thalassaemia and which otherwise leads to toxic accumulation of iron. Combination of an MTP-2 inhibitor with an activin receptor ligand trap, or with erythropoietin, provides additional therapeutic effects.

Provided is a method of treating or alleviating one or more pathologies associated with β- thalassemia in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising an effective amount of an anti-matriptase-2 antibody or antigen-binding fragment thereof. The one or more pathologies may be insoluble liver iron stores: α-globin precipitates in ery throid cells; reactive oxidized species formation; apoptosis of erythroid cells; reticulocytosis; or a combination thereof.

The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and / or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine proteases (e.g. Cathepsin B). The present invention also relates to various methods of using the inhibitor compounds to treat or prevent viral infections, including those caused by coronaviruses and influenza, conditions associated with KLK5, various malignancies, pre-malignant conditions, and cancer.

A kind of metal matrix protease responsive polyphenol functionalized hydrogel and preparation method thereof.The present application belongs to the technical field of medicine, discloses a kind of metal matrix protease (MMPs) responsive polyphenol functionalized hydrogel and preparation method and application thereof.The present application prepares polyphenol functionalized hydrogel by film dispersion method.The method preparation process is simple, low in cost, good in stability, high in repeatability.TM / PT / Cel-Cu can solve the problems of poor water solubility and low bioavailability of Cel-Cu on one hand;On the other hand, by adding tea polyphenols, the stability and viscosity of the hydrogel are enhanced.The hydrogel preparation process is simple, fast, easy to scale up and industrialized production, and has good development prospect in clinical application transformation.

To provide a method for identifying a new substrate for a protease, and a method for using the substrate in various therapeutic, diagnostic and preventive applications.SOLUTION: The present invention relates generally to polypeptides comprising a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator (uPA), activatable antibodies and other large molecules comprising a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator, and methods of making and using these polypeptides comprising a cleavable moiety that is a substrate for at least one protease selected from matriptase and u-plasminogen activator in a variety of therapeutic, diagnostic, and prophylactic indications.SELECTED DRAWING: Figure 4A